02.06.2016
WILEX AG DE000A11QVV0
DGAP-News: WILEX AG: WILEX AG announces change on the Executive Management Board
DGAP-News: WILEX AG / Key word(s): Change of Personnel
WILEX AG: WILEX AG announces change on the Executive Management Board
02.06.2016 / 13:57
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PRESS RELEASE
WILEX AG announces change on the Executive Management Board
Munich, Germany, 2 June 2016 - WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE)
today announced that Professor Andreas Pahl has been appointed to the
company's Executive Management Board to serve as the new Head of Research
and Development. Professor Pahl will take over this capacity with immediate
effect.
Professor Andreas Pahl has worked successfully as Chief Scientific Officer
and member of the executive management of WILEX's subsidiary Heidelberg
Pharma GmbH since September 2012, and can look back on 20 years' experience
in research and higher education. Prior to his position at Heidelberg
Pharma, he spent four years as Head of Late Pharmacology at Nycomed and
Takeda Pharmaceuticals. After graduating in chemistry from the University
of Berlin, he spent several years lecturing at TU Berlin and the University
of Erlangen-Nuremberg (FAU), at which he was also appointed Professor of
Pharmacology and Toxicology. Professor Pahl will continue to perform his
teaching duties at FAU.
Professor Christof Hettich, Chairman of the Supervisory Board of WILEX AG,
commented: "Over the years, we have come to know Andreas Pahl not only as a
competent research scientist with a strong set of leadership skills but
also as a valuable and greatly appreciated contact for partners in our ADC
business."
Dr Jan Schmidt-Brand, CFO and Spokesman of the Executive Management Board,
added: "We warmly welcome Andreas Pahl's appointment: it gives us a Head of
Research and Development who is able to draw on many years of experience in
R&D and who is not only thoroughly familiar with our day-to-day business
but is deeply committed to powerfully driving this business forward."
Professor Andreas Pahl said: "I am very pleased to accept the position of
CSO at WILEX AG and am aware of the great responsibility this entails.
Although acquiring investors and partners for our technology while securing
funding is a constant challenge, this is balanced by the huge opportunities
presented once we provide proof of clinical effectiveness, as well as good
safety and tolerability in patients. As in the past, I will continue to
work with great enthusiasm on the development and utilisation of our ATAC
technology."
About WILEX and Heidelberg Pharma
WILEX AG is a biopharmaceutical company which discontinued all clinical
development activities at its Munich site and now exercises a holding
function as the Group parent. Research and development focus on the
operations of its subsidiary Heidelberg Pharma GmbH in Ladenburg, which
primarily advances the development of the innovative ADC platform
technology for Antibody-Targeted Amanitin Conjugates (ATAC technology) and
provides preclinical drug research and development services. WILEX has the
diagnostic and therapeutic drug candidates REDECTANE(R) and RENCAREX(R),
which are available for out-licensing and further development in Phase III
for external partners. WILEX is listed at the Frankfurt Stock Exchange:
ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available
at http://www.wilex.com/.
Contact IR/PRsupport WILEX AG MC Services AG Sylvia Wimmer Katja Arnold (CIRO) Corporate Communications Executive Director & Partner Tel.: +49 (0)89-41 31 38-29 Tel.: +49 (0)89-210 228-40 Email: investors[at]wilex.com Mobile: +49 (0)160 9360 3022 Grillparzerstr. 18, 81675 Email: katja.arnold[at]mc-services.eu Munich, GermanyThis communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward- looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments. --------------------------------------------------------------------------- 02.06.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: WILEX AG Grillparzerstr. 18 81675 München Germany Phone: +49 (0)89 41 31 38 - 0 Fax: +49 (0)89 41 31 38 - 99 E-mail: [email protected] Internet: www.wilex.com ISIN: DE000A11QVV0 WKN: A11QVV Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart End of News DGAP News Service --------------------------------------------------------------------------- 468751 02.06.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
WILEX AG ISIN: DE000A11QVV0 können Sie bei EQS abrufen
Biotechnologie , A11QVV , HPHA , XETR:WL6